{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:33:05Z","timestamp":1772253185652,"version":"3.50.1"},"reference-count":32,"publisher":"Sociedade Brasileira de Cardiologia","issue":"4","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Bras. Cardiol."],"abstract":"<jats:p>Resumo  Fundamento  A edoxabana \u00e9 um anticoagulante oral que se mostrou segura e eficaz na preven\u00e7\u00e3o de acidente vascular cerebral em pacientes com fibrila\u00e7\u00e3o atrial (FA). Dada a ampla utiliza\u00e7\u00e3o da edoxabana desde sua aprova\u00e7\u00e3o, \u00e9 crucial avaliar seu desempenho no contexto cl\u00ednico brasileiro.  Objetivos  O objetivo do estudo foi descrever a seguran\u00e7a e a efetividade da edoxabana no tratamento de pacientes com FA no Brasil.  M\u00e9todos  O EdoBRA \u00e9 um estudo multic\u00eantrico, prospectivo, observacional, conduzido em 30 centros de pesquisa no Brasil. Eventos de sangramento foram considerados medidas de seguran\u00e7a, e eventos cardiovasculares foram considerados para medidas de efetividade. An\u00e1lises descritivas foram realizadas. Curvas de Kaplan-Meier foram geradas para an\u00e1lise do tempo para o evento, e um intervalo de confian\u00e7a de 95% usado conforme apropriado.  Resultados  Entre os 705 pacientes recrutados, 590 foram inclu\u00eddos na an\u00e1lise por apresentarem pelo menos um evento relatado ou durante o seguimento. As m\u00e9dias (\u00b1DP) dos escores de risco CHA2DS2-VASc e HAS-BLED foram, respectivamente, 3 (3,3 \u00b1 1,6) e 2 (1,8 \u00b1 1,2). Durante o acompanhamento de um ano, foram relatados nove sangramentos maiores, incluindo cinco casos de sangramento gastrointestinal [PI 0,85 (IC95% =0,82; 0,88]). Entre os eventos cardiovasculares registrados (n=68), houve quatro eventos de acidente vascular cerebral [PI 0,68 (IC 95% 0,65; 0,71)], um ataque isqu\u00eamico transit\u00f3rio [PI 0,17 (IC 95% 0,16; 0,18)] e um tromboembolismo venoso [PI 0,17 (IC 95% 0,16; 0,18)]. Nenhum evento emb\u00f3lico sist\u00eamico foi relatado.  Conclus\u00e3o  Em uma popula\u00e7\u00e3o idosa com v\u00e1rias comorbidades, recebendo edoxabana como tratamento de rotina para FA, as taxas de evento cardiovasculares sangramento maior foram baixas.<\/jats:p>","DOI":"10.36660\/abc.20240589","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:38:36Z","timestamp":1744882716000},"source":"Crossref","is-referenced-by-count":1,"title":["Efetividade e Seguran\u00e7a da Edoxabana nos Cuidados Cl\u00ednicos de Rotina de Pacientes com Fibrila\u00e7\u00e3o Atrial no Brasil: Estudo Prospectivo de Acompanhamento de 1 Ano \u2013 EdoBRA"],"prefix":"10.36660","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-8690","authenticated-orcid":false,"given":"Dalton Bertolim","family":"Precoma","sequence":"first","affiliation":[{"name":"Sociedade Hospitalar Angelina Caron,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Paletta da","family":"Silva","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Brasil Farmaceutica LTDA,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Carlos Santana","family":"Passos","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrado Roberto","family":"Hoffman Filho","sequence":"additional","affiliation":[{"name":"Hospital Regional Hans Dieter Schmidt,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-7328","authenticated-orcid":false,"given":"F\u00e1bio Serra","family":"Silveira","sequence":"additional","affiliation":[{"name":"JMF Cl\u00ednica do Cora\u00e7\u00e3o,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Tarc\u00edsio Medeiros de","family":"Vasconcelos","sequence":"additional","affiliation":[{"name":"Real e Benem\u00e9rita Associa\u00e7\u00e3o Portuguesa de Benefic\u00eancia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-9209","authenticated-orcid":false,"given":"S\u00e9rgio Luiz","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil; Universidade Regional de Blumenau,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-5916","authenticated-orcid":false,"given":"Artur Haddad","family":"Herdy","sequence":"additional","affiliation":[{"name":"Instituto de Cardiologia de Santa Catarina,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ritter","sequence":"additional","affiliation":[{"name":"IQVIA Brasil,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9922","authenticated-orcid":false,"given":"Daniely","family":"Freitas-Alves","sequence":"additional","affiliation":[{"name":"IQVIA Brasil,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Francisco Kerr","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica de Campinas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","published-online":{"date-parts":[[2025]]},"reference":[{"issue":"1","key":"ref1","article-title":"Atrial Fibrillation","volume":"8","author":"Brundel BJJM","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association","volume":"139","author":"Benjamin EJ","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jce.15759","article-title":"Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Complications (Literature Review)","volume":"34","author":"Bizhanov KA","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"23","key":"ref5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January CT","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report","volume":"154","author":"Lip GYH","year":"2018","journal-title":"Chest"},{"key":"ref7","series-title":"Lixiana (Edoxabana) - Parecer P\u00fablico de Avalia\u00e7\u00e3o de Medicamento","year":"2018"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa","volume":"55","author":"Parasrampuria DA","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"ref9","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jacc.2018.07.037","article-title":"Edoxaban versus Warfarin in Latin American Patients with Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial","volume":"72","author":"Corbal\u00e1n R","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"FI1","key":"ref10","doi-asserted-by":"crossref","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for Stroke Prevention in Atrial Fibrillation in Routine Clinical Care: 1-Year Follow-Up of the Prospective Observational ETNA-AF-Europe Study","volume":"7","author":"Groot JR","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20230392i","article-title":"Study Design of a Brazilian Observational Study of Edoxaban in Patients with Atrial Fibrillation (EdoBRA)","volume":"121","author":"Pr\u00e9coma DB","year":"2024","journal-title":"Arq Bras Cardiol"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031342","article-title":"Discontinuation of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation: A Population-Based Cohort Study Using Primary Care Data from The Health Improvement Network in the UK","volume":"9","author":"Ruig\u00f3mez A","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/03007995.2021.1901223","article-title":"Real-World Effectiveness and Safety of Rivaroxaban versus Warfarin Among Non-Valvular Atrial Fibrillation Patients with Obesity in a US Population","volume":"37","author":"Berger JS","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"ref14","series-title":"Censo Demogr\u00e1fico 2022","year":"2022"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4070\/kcj.2018.0261","article-title":"Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges","volume":"48","author":"Sabbag A","year":"2018","journal-title":"Korean Circ J"},{"issue":"20","key":"ref16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012554","article-title":"Incidence and Predictors of Atrial Fibrillation Progression","volume":"8","author":"Blum S","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/medicina55080497","article-title":"Subclinical and Asymptomatic Atrial Fibrillation: Current Evidence and Unsolved Questions in Clinical Practice","volume":"55","author":"Ballatore A","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMcp2023658","article-title":"Atrial Fibrillation","volume":"384","author":"Michaud GF","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"ref19","article-title":"CHA2DS2-VASc Score Predicts Exercise Intolerance in Young and Middle-Aged Male Patients with Asymptomatic Atrial Fibrillation","volume":"8","author":"Yi JE","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/jcm10040573","article-title":"Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program","volume":"10","author":"Caterina R","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel J","year":"2021","journal-title":"Europace"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","article-title":"Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients-Results from the Dresden Non-Interventional Oral Anticoagulation Registry","volume":"17","author":"Beyer-Westendorf J","year":"2015","journal-title":"Europace"},{"issue":"14","key":"ref23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a Real-World, Prospective, Observational Study of Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation","volume":"37","author":"Camm AJ","year":"2016","journal-title":"Eur Heart J"},{"key":"ref24","article-title":"Inequalities in Unmet Need for Health Care Services and Medications in Brazil: A Decomposition Analysis","volume":"19","author":"Coube M","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003735","article-title":"Sudden Cardiac Death in Patients with Atrial Fibrillation: Insights from the ENGAGE AF-TIMI 48 Trial","volume":"5","author":"Eisen A","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2017.09.029","article-title":"Effectiveness and Safety of Oral Anticoagulation with Non-Vitamin K Antagonists Compared to Well-Managed Vitamin K Antagonists in Na\u00efve Patients with Non-Valvular Atrial Fibrillation: Propensity Score Matched Cohort Study","volume":"249","author":"Denas G","year":"2017","journal-title":"Int J Cardiol"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients","volume":"49","author":"Lip GYH","year":"2018","journal-title":"Stroke"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ehjcvp\/pvac042","article-title":"Edoxaban for Stroke Prevention in Atrial Fibrillation and Age-Adjusted Predictors of Clinical Outcomes in Routine Clinical Care","volume":"9","author":"Kirchhof P","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/europace\/euz032","article-title":"Association between Antithrombotic Treatment and Outcomes at 1-Year Follow-Up in Patients with Atrial Fibrillation: The EORP-AF General Long-Term Registry","volume":"21","author":"Boriani G","year":"2019","journal-title":"Europace"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial","volume":"129","author":"Giugliano RP","year":"2016","journal-title":"Am J Med"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","DOI":"10.1186\/s13690-022-01012-z","article-title":"COVID-19 Mortality in Brazil, 2020-21: Consequences of the Pandemic Inadequate Management","volume":"80","author":"Szwarcwald CL","year":"2022","journal-title":"Arch Public Health"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292463","article-title":"Identifying and Understanding the Care Pathway of Patients with Atrial Fibrillation in Brazil and the Impact of the COVID-19 Pandemic: A Mixed-Methods Study","volume":"18","author":"Goulart AC","year":"2023","journal-title":"PLoS One"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":["Effectiveness and Safety of Edoxaban in the Routine Clinical Care of Atrial Fibrillation Patients in Brazil: Prospective 1-Year Follow-Up Study \u2013 EdoBRA"],"link":[{"URL":"https:\/\/abccardiol.org\/wp-content\/uploads\/articles_xml\/0066-782x-abc-122-4-e20240589\/0066-782x-abc-122-4-e20240589.x95083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:38:53Z","timestamp":1744882733000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/efetividade-e-seguranca-da-edoxabana-nos-cuidados-clinicos-de-rotina-de-pacientes-com-fibrilacao-atrial-no-brasil-estudo-prospectivo-de-acompanhamento-de-1-ano-edobra\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"alternative-id":["S0066-782X2025000400302"],"URL":"https:\/\/doi.org\/10.36660\/abc.20240589","relation":{"is-translation-of":[{"id-type":"doi","id":"10.36660\/abc.20240589i","asserted-by":"subject"},{"id-type":"doi","id":"10.36660\/abc.20240589i","asserted-by":"object"}]},"ISSN":["1678-4170","0066-782X"],"issn-type":[{"value":"1678-4170","type":"electronic"},{"value":"0066-782X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20240589"}}